Biogen Message Board - Msg: 231473

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 179.89

+2.1%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael H. Dragon who wrote (1)	8/20/1996 7:15:00 AM
From: Harold Engstrom	of 1686

Mike, glad there is another Biogen fan out there. I think you are right about the $100M/$1 per share earnings. The math should work out better (with only 35M shares outstanding), but no doubt Biogen will use a huge amount of the revenues for R&D, infrastructure and investment. In the company's Q2 conference call with the investment community, they said they were adding 1,000+ patients per week...I suspect the number is closer to 1,500+. That would put their current patient count at over 12,000 patients and put them on target for 30,000 before the end of the year. European approvals are set for early next year, and Biogen's patents are very strong - Schering and Serono are not anticipated to be problematic. Next quarter's earnings may be in excess of $1: the company intends to take advantage of tax credits in a one-time fashion giving them a starting per share earnings base of $0.605. I wonder how Ontogeny will play out, too. But, I hope a major pharmaceutical does not buy Biogen: they have too much potential as an independent company.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next